Citations Report

Citation Index - Clinical Investigation [920 Articles]

The articles published in Clinical Investigation have been cited 920 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Clinical Investigation.

  • Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, et al. (2013) Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood121:1296-303

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders. United States patent US 9,220,755

    View at Publisher | View at Google Scholar
  • Schrum JP, Bancel S, Afeyan NB, Ejebe K, inventors; Moderna Therapeutics, et al. (2016) Engineered nucleic acids and methods of use thereof. United States patent US 9,447,164

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, Weiss R, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides for treating galactosylceramidase protein deficiency. United States patent US 9,089,604

    View at Publisher | View at Google Scholar
  • De Fougerolles A, Elbashir SM, inventors; Modernatx, Inc (2017) Delivery and formulation of engineered nucleic acids. United States patent US 9,533,047

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding aquaporin-5. United States patent US 9,220,792

    View at Publisher | View at Google Scholar
  • Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, et al. (2016) Pushing estrogen receptor around in breast cancer. Endocrine-related cancer 23: T227-T241.

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding basic helix-loop-helix family member E41. United States patent US 9,107,886

    View at Publisher | View at Google Scholar
  • Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, et al. (2016) Androgen receptor signaling pathways as a target for breast cancer treatment. Endocrine-Related Cancer 23: R485-R498.

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2016) Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders. United States patent US 9,233,141

    View at Publisher | View at Google Scholar
  • Machaj AS (2014) Breast Cancer in PTEN Hamartoma Tumor Syndrome: Can a Predictive Fingerprint be Identified? (Doctoral dissertation, Case Western Reserve University).

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, Weiss R, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator. United States patent US 9,050,297

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1. United States patent US 9,095,552

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2016) Modified polynucleotides encoding apoptosis inducing factor 1. United States patent US 9,301,993

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding granulysin. United States patent US 9,216,205

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2016) Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1. United States patent US 9,255,129

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding citeD4. United States patent US 9,114,113

    View at Publisher | View at Google Scholar
  • Bancel S, Chakraborty T, De Fougerolles A, Elbashir SM, John M, et al. (2015) Modified polynucleotides for the production of biologics and proteins associated with human disease. United States patent US 8,999,380

    View at Publisher | View at Google Scholar
  • Hensel M, Brust J, Plöger C, Schuster D, Memmer ML, et al. (2012) Excellent long-term survival of 170 patients with Waldenström’s macroglobulinemia treated in private oncology practices and a university hospital. Annals of hematology91:1923-8

    View at Publisher | View at Google Scholar
  • D'souza A, Ansell S, Reeder C, Gertz MA (2013) Waldenström macroglobulinaemia: the key questions. British journal of haematology162:295-303

    View at Publisher | View at Google Scholar
  • Coimbra S, Neves R, Lima M, Belo L, Santos-Silva A (2014) Waldenström's macroglobulinemia-a review. Revista da Associação Médica Brasileira60:490-9

    View at Publisher | View at Google Scholar
  • Schrum JP, Siddiqi S, Ejebe K, inventors; Moderna Therapeutics, Inc (2016) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof. United States patent US 9,334,328

    View at Publisher | View at Google Scholar
  • Hoge SG, De Fougerolles A, Ellsworth JL, inventors; Moderna Therapeutics, Inc (2015) Compositions and methods of altering cholesterol levels. United States patent US 8,980,864

    View at Publisher | View at Google Scholar
  • Bancel S, Chakraborty T, De Fougerolles A, Elbashir SM, John M, et al. (2016) United States patent US 9,254,311.

    View at Publisher | View at Google Scholar
  • De Fougerolles A, Elbashir SM, inventors; Moderna Therapeutics, Inc (2015) Split dose administration. United States patent US 9,186,372

    View at Publisher | View at Google Scholar
  • Vuorio A, Tikkanen MJ, Kovanen PT (2014) inhibition of hepatic microsomal triglyceride transfer protein–a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vascular health and risk management 10: 263.

    View at Publisher | View at Google Scholar
  • Vorsanger M, Underberg JA (2013) New Treatment Approaches for Dyslipidemia and its Management. Current Cardiovascular Risk Reports 7: 395-400.

    View at Publisher | View at Google Scholar
  • Enck P, Grundy D, Klosterhalfen S (2012) A novel placebo-controlled clinical study design without ethical concerns–The free choice paradigm. Medical hypotheses 79: 880-882.

    View at Publisher | View at Google Scholar
  • Steinvorth SM, Röver C, Schneider S, Nicholas R, Straube S, et al. (2013) Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression. Multiple Sclerosis Journal 19: 1580-1586.

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2016) Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins. United States patent US 9,303,079

    View at Publisher | View at Google Scholar
  • Schneider S, Schmidli H, Friede T (2013) Blinded sample size re‐estimation for recurrent event data with time trends. Statistics in medicine 32: 5448-5457.

    View at Publisher | View at Google Scholar
  • Schneider S, Schmidli H, Friede T (2013) Blinded and unblinded internal pilot study designs for clinical trials with count data. Biometrical Journal 55: 617-633.

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, Weiss R, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides for treating protein deficiency. United States patent US 9,061,059

    View at Publisher | View at Google Scholar
  • Mütze T, Munk A, Friede T (2016) Design and analysis of three‐arm trials with negative binomially distributed endpoints. Statistics in medicine 35: 505-521.

    View at Publisher | View at Google Scholar
  • Friede T, Mütze T. Gold Standard Designs for Clinical Trials with Overdispersed Count Data.

    View at Publisher | View at Google Scholar
  • Mütze T, Munk A (2013) Design and analysis of clinical non-inferiority trials with active and placebo control for count data.

    View at Publisher | View at Google Scholar
  • De Fougerolles A, Wood KM, Valencia P, inventors; Moderna Therapeutics, Inc (2016) Formulation and delivery of PLGA microspheres. United States patent US 9,295,689

    View at Publisher | View at Google Scholar
  • Bancel S, Schrum JP, Aristarkhov A, inventors; Moderna Therapeutics, Inc (2016) Engineered nucleic acids and methods of use thereof. United States patent US 9,464,124

    View at Publisher | View at Google Scholar
  • Jiang YH, Liu HT, Kuo HC (2014) Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. PloS one 9: e91609.

    View at Publisher | View at Google Scholar
  • Jiang YH, Kuo HC (2014) Urothelial Dysfunction and Increased Suburothelial Inflammation of Urinary Bladder Are Involved in Patients with Upper Urinary Tract Urolithiasis–Clinical and Immunohistochemistry Study. PloS one 9: e110754.

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, Weiss R, inventors; Moderna Therapeutics, Inc (2016) Modified polynucleotides for the production of nuclear proteins. United States patent US 9,283,287

    View at Publisher | View at Google Scholar
  • Anderson KC, Richardson PG, Weller E, Matous J, Chuma S, et al. (2015) Results of the phase II trial of single agent histone deacetylase inhibitor.

    View at Publisher | View at Google Scholar
  • Merrett ND (2014) Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects. World Journal of Gastroenterology: WJG 20:12892.

    View at Publisher | View at Google Scholar
  • Yoo C, Ryu MH, Park YS, Yoo MW, Park SR, Ryoo BY, Jang SJ, Yook JH, Kim BS, Kang YK. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence. Annals of surgical oncology 22: 2940-2947.

    View at Publisher | View at Google Scholar
  • Yoon S, Yoo C, Ryu MH, Kang MJ, Ryoo BY, et al. (2017) Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB–IV gastric cancer. Gastric Cancer 20: 182-189.

    View at Publisher | View at Google Scholar
  • Leblond V, Merlini G, Treon SP, Rodig S, Delabie J (2015) Waldenström’s Macroglobulinemia. In: Rare Lymphomas. Springer Berlin Heidelberg

    View at Publisher | View at Google Scholar
  • Merrett ND, Merrett ND (2014) Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects.

    View at Publisher | View at Google Scholar
  • Schrum JP, Bancel S, Afeyan NB, inventors; Moderna Therapeutics, Inc (2015) Engineered nucleic acids and methods of use thereof. United States patent US 9,181,319

    View at Publisher | View at Google Scholar
  • Chakraborty T, De Fougerolles A, inventors; Moderna Therapeutics, Inc (2015) Modified polynucleotides encoding septin-4. United States patent US 9,149,506

    View at Publisher | View at Google Scholar
  • Hong P, Liu Y, Li H (2015) Comparison of the efficacy and safety between interspinous process distraction device and open decompression surgery in treating lumbar spinal stenosis: a meta analysis. Journal of Investigative Surgery 28: 40-49.

    View at Publisher | View at Google Scholar

Relevant Topics